FIGURE 5.

UC-MSC trigger reprogramming of M1 toward M2-Macrophage. (A) Percentage of CD3⁺ T cell suppression in αCD3/CD28-activated PBMNC/UC-MSC or monocyte-depleted (CD14^neg)-PBMNC/UC-MSC cocultures (*p < 0.01, n = 3). (B) CD14^pos monocytes were preconditioned with UC-MSC under experimental inflammation. CD14^pos cells were purified, seeded in the upper chamber of 1 μm-pore transwell inserts and exposed to activated autologous PBMNC (CD14^pos/PBMNC), or activated PBMNC/UC-MSC cocultures (CD14^pos/PBMNC+MSC) for 5 days. Preconditioned monocytes (CD14^pos/PBMNC or CD14^pos/PBMNC+MSC) were further transferred to activated autologous CD3⁺ cells and T cell suppression was determined 5 days post culture. Expression of M2-like markers CD206, CD163, and CD301 in preconditioned CD14^pos monocytes at day 5 was determined (# vs. CD14^pos/PBMNC, p = p < 0.05, n = 3–4). (C) Percentage of CD3⁺ T cell proliferation after culture with CD14^pos/PBMNC or CD14^pos/PBMNC+MSC monocytes in a ratio 10:1 (CD3⁺:CD14^pos) (# vs. CD14^pos/PBMNC, p < 0.05, n = 3). (D) Supernatants from CD14^pos/PBMNC or CD14^pos/PBMNC+MSC were collected and analyzed for cytokine, chemokines and growth factor production following preconditioning experiments (** vs. CD14^pos/PBMNC, p = 0 < 0.05, n = 4–8).